8 Jul 2015 17:15
8 July 2015
Cambridge Cognition Holdings Plc
('Cambridge Cognition' or the 'Company')
Re: Directorate Change
Further to the Company's announcement of 1 July 2015, the following information regarding the appointment of Steven John Powell, aged 53, is disclosed pursuant to paragraph (g) of Schedule Two to the AIM Rules for Companies.
Other directorships and partnerships held:
Current | Within the last 5 years |
CE Bioscience Limited | Andron Pharma Limited |
Chroma Therapeutics Limited | Fast Track Pharma (Holdings) Limited |
Fast Track Pharma Limited | Plethora Solutions Holdings PLC |
Macrotarg Limited | Plethora Solutions Limited |
The Brain Tumour Charity | Plethora Therapeutics Limited |
The Native Antigen Company Limited | The Urology Company Holdings Limited |
The Truffaldino Partnership Limited | The Urology Company Limited |
There is no further information on Dr. Powell required to be disclosed under Schedule Two, paragraph (g) (i)-(viii) of the AIM Rules for Companies.
Enquiries:
Cambridge Cognition Holdings plc | www.cambridgecognition.com | |
Michael Lewis, Chairman Steven Powell, Chief Operating Officer | Tel: 01223 810 700 | |
Nick Walters, Chief Financial Officer | ||
finnCap Ltd (Nomad and Broker) | Tel: 020 7220 0500 | |
Geoff Nash/Simon Hicks | (Corporate Finance) | |
Malar Velaigam | (Corporate Broking) | |
Walbrook PR Ltd | Tel: 020 7933 8780 or camcog@walbrookpr.com | |
Paul McManus | Mob: 07980 541 893 | |
Lianne Cawthorne | Mob: 07584 391 303 | |
About Cambridge Cognition
Cambridge Cognition is a world leading provider of computerised cognitive assessment products. The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic scientists in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function. In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the Cantab mobile brand, to improve the monitoring, management and maintenance of cognitive health and wellbeing. Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families.
Cambridge Cog (COG)